Drugs / mibefradil
mibefradil
also known as
Mibefradil dihydrochloride · Mibefradil hydrochloride · Posicor · Posicor 100 · Posicor 50 · RO 40-5967/001
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02202993 | Aug 2014 → Sep 2017 | glioblastoma | Cavion, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01480050 | May 2012 → Aug 2015 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT01550458 | Feb → Jun 2012 | — | Cavion, Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mibefradil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01550458 ↗ |
| Known as | Mibefradil dihydrochloride | “Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT01480050 ↗ |
| Known as | Mibefradil hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL45816 ↗ |
| Known as | Posicor | ChEMBL registry synonym — accepted as the source's own label CHEMBL45816 ↗ |
| Known as | Posicor 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL45816 ↗ |
| Known as | Posicor 50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL45816 ↗ |
| Known as | RO 40-5967/001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL45816 ↗ |
| Action | Inhibit | “Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT01480050 ↗ |
| Modality | Small molecule | — CHEMBL45816 ↗ |
| Route | Oral | “Patients receive mibefradil dihydrochloride orally (PO) 4 times a day on days 1-7 (days 1-8 on first course)” NCT01480050 ↗ |